Study design (if review, criteria of inclusion for studies)
Prospective study
Participants
198 patients with cystic fibrosis aged 2-19 with CF.
Interventions
Live-attenuated intranasal influenza vaccine (LAIV) for seasonal immunization. Vaccinees were followed prospectively for 55 days after vaccination (day 0)
Outcome measures
Information on adverse events was collected. Bayesian change-point analysis was used to identify the risk period following LAIV during which participants had a higher risk of reporting adverse events.
Main results
There was a higher risk of reporting serious adverse events (SAEs) (aIRR 1.45, 95% CrI (0.29, 5.17)) and solicited symptoms during days 0-6 of follow-up compared to control period days 7-55. However, most SAEs were not causally related to LAIV and the solicited symptom episodes were brief, usually lasting 1-2 days. There was no increased risk of antibiotic prescriptions for respiratory conditions in the risk vs. control periods (aIRR 0.48, 95% CrI (0.23, 0.91)).
Authors' conclusions
Adverse events were most common 0-6 days after LAIV administration but were generally benign and self-limiting. Pulmonary exacerbations did not increase in frequency.